Comments
Loading...

4D Molecular Therapeutics

FDMTNASDAQ
Logo brought to you by Benzinga Data
$15.39
-1.43-8.50%
Last update: 9:38 AM
15 minutes delayed
Consensus Rating1
Buy
Highest Price Target1
$81.00
Lowest Price Target1
$13.00
Consensus Price Target1
$39.45

4D Molecular Therapeutics (NASDAQ:FDMT) Stock, Analyst Ratings, Price Targets, Forecasts

4D Molecular Therapeutics Inc has a consensus price target of $39.45 based on the ratings of 12 analysts. The high is $81 issued by Goldman Sachs on February 7, 2024. The low is $13 issued by SVB Securities on April 13, 2023. The 3 most-recent analyst ratings were released by Leerink Partners, HC Wainwright & Co., and HC Wainwright & Co. on September 19, 2024, September 19, 2024, and August 9, 2024, respectively. With an average price target of $36 between Leerink Partners, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 133.92% upside for 4D Molecular Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Jun
2
Jul
0
0
0
0
Aug
2
Sep
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Leerink Partners
HC Wainwright & Co.
RBC Capital
BMO Capital
Chardan Capital

1calculated from analyst ratings

Analyst Ratings for 4D Molecular Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for 4D Molecular Therapeutics (FDMT) stock?

A

The latest price target for 4D Molecular Therapeutics (NASDAQ:FDMT) was reported by Leerink Partners on September 19, 2024. The analyst firm set a price target for $36.00 expecting FDMT to rise to within 12 months (a possible 133.92% upside). 20 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for 4D Molecular Therapeutics (FDMT)?

A

The latest analyst rating for 4D Molecular Therapeutics (NASDAQ:FDMT) was provided by Leerink Partners, and 4D Molecular Therapeutics reiterated their outperform rating.

Q

When was the last upgrade for 4D Molecular Therapeutics (FDMT)?

A

The last upgrade for 4D Molecular Therapeutics Inc happened on November 15, 2022 when Goldman Sachs raised their price target to $68. Goldman Sachs previously had a neutral for 4D Molecular Therapeutics Inc.

Q

When was the last downgrade for 4D Molecular Therapeutics (FDMT)?

A

The last downgrade for 4D Molecular Therapeutics Inc happened on August 12, 2022 when SVB Leerink changed their price target from $28 to $12 for 4D Molecular Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for 4D Molecular Therapeutics (FDMT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of 4D Molecular Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for 4D Molecular Therapeutics was filed on September 19, 2024 so you should expect the next rating to be made available sometime around September 19, 2025.

Q

Is the Analyst Rating 4D Molecular Therapeutics (FDMT) correct?

A

While ratings are subjective and will change, the latest 4D Molecular Therapeutics (FDMT) rating was a reiterated with a price target of $40.00 to $36.00. The current price 4D Molecular Therapeutics (FDMT) is trading at is $15.39, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch